You are here: Home: PCU 2 | 2006: Daniel P Petrylak, MD: Select publications

SELECT PUBLICATIONS

Akakura K et al. Effects of intermittent androgen suppression on androgen-depen dent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71(9):2782-90. Abstract

Arlen PM, Gulley JL. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. Future Oncol 2005;1(1):19-22. Abstract

Beer TM et al. Multiple cycles of intermittent chemotherapy in metastatic androgen independent prostate cancer. Br J Cancer 2004;91(8):1425-7. Abstract

Bhandari MS et al. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005;23(32):8212-8. Abstract

Burgess EF, Roth BJ. Changing perspectives of the role of chemotherapy in advanced prostate cancer. Urol Clin North Am 2006;33(2):227-36. Abstract

Eggener SE et al. Enhancement of intermittent androgen ablation by “off-cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006;66(5):495-502. Abstract

Gulley JL et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005;173(5):1567-71. Abstract

Hainsworth JD et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Clin Genitourin Cancer 2006;4(4):287-92. Abstract

Higano C et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64(6):1182-6. Abstract

Hobisch A et al. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression. Prostate 2004;59(4):401-8.Abstract

Kramer G et al. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 2006;94(11):1592-8. Abstract

Mottet N et al. Intermittent androgen castration: A biological reality during intermittent treatment in metastatic prostate cancer? Urol Int 2005;75(3):204-8. Abstract

Oh WK et al. Response to second-line chemotherapy in patients with hormone refrac­tory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67(6):1235-40. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and predni­sone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Peyromaure M et al. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: Long-term experience. Urology 2005;65(4):724-9. Abstract

Ryan CJ et al. Angiogenesis inhibition plus chemotherapy for metastatic hormone refrac­tory prostate cancer: History and rationale. Urol Oncol 2006;24(3):250-3. Abstract

Sato N et al; Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multi­center study. Urology 2004;64(2):341-5. Abstract

Sato N et al. Intermittent androgen suppression delays progression to androgen-indepen­dent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58(2):139-46. Abstract

Smith MR et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918-25. Abstract

Spry NA et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006;42(8):1083-92. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Winquist E et al. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: A systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6(1):112;[Epub ahead of print]. Abstract

Wright JL et al. Intermittent androgen deprivation: Clinical experience and practical applications. Urol Clin North Am 2006;33(2):167-79, vi. Abstract

Home